Personalized Dosing of Nicotine Replacement (NRT to Effect)
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Medications for smoking cessation are currently only effective in helping a minority of
smokers quit. Drug development is slow and expensive, so there is much interest in optimizing
the effectiveness of existing treatments and medications. Current standard doses of nicotine
replacement therapy (NRT) are not effective for many smokers and in many cases provide less
nicotine compared to when a smoker is smoking their usual number of cigarettes. The proposed
study will test if a personalized dose of nicotine patch (up to 84mg) will improve quitting
success in those who do not respond to a standard dose of NRT (21mg).
Phase:
Phase 4
Details
Lead Sponsor:
Centre for Addiction and Mental Health
Collaborators:
Canadian Cancer Society (CCS) Canadian Cancer Society Research Institute (CCSRI) Ottawa Heart Institute Research Corporation